ABSTRACT
OBJECTIVES: Research has demonstrated that chronic stress experienced early in life can lead to impairments in memory and learning. These deficits are attributed to an imbalance in the interaction between glucocorticoids, the end product of the hypothalamic-pituitary-adrenal (HPA) axis, and glucocorticoid receptors in brain regions responsible for mediating memory, such as the hippocampus. This imbalance can result in detrimental conditions like neuroinflammation. The aim of this study was to assess the impact of sumatriptan, a selective agonist for 5-HT 1B/1D receptors, on fear learning capabilities in a chronic social isolation stress model in mice, with a particular focus on the role of the HPA axis. METHODS: Mice were assigned to two opposing conditions, including social condition (SC) and isolated condition (IC) for a duration of five weeks. All mice underwent passive avoidance test, with their subsequent freezing behavior serving as an indicator of fear retrieval. Mice in the IC group were administered either a vehicle, sumatriptan, GR-127935 (a selective antagonist for 5-HT 1B/1D receptors), or a combination of sumatriptan and GR-127935 during the testing sessions. At the end, all mice were sacrificed and samples of their serum and hippocampus were collected for further analysis. RESULTS: Isolation was found to significantly reduce freezing behavior (p<0.001). An increase in the freezing response among IC mice was observed following the administration of varying doses of sumatriptan, as indicated by a one-way ANOVA analysis (p<0.001). However, the mitigating effects of sumatriptan were reversed upon the administration of GR-127935. An ELISA assay conducted before and after the passive avoidance test revealed no significant change in serum corticosterone levels among SC mice. In contrast, a significant increase was observed among IC mice, suggesting hyper-responsiveness of the HPA axis in isolated animals. This hyper-responsiveness was ameliorated following the administration of sumatriptan. Furthermore, both the sumatriptan and SC groups exhibited a similar trend, showing a significant increase in the expression of hippocampal glucocorticoid receptors following the stress of the passive avoidance test. Lastly, the elevated production of inflammatory cytokines (TNF-α, IL-1ß) observed following social isolation was attenuated in the sumatriptan group. CONCLUSION: Sumatriptan improved fear learning probably through modulation of HPA axis and hippocampus neuroinflammation.
Subject(s)
Hypothalamo-Hypophyseal System , Sumatriptan , Mice , Animals , Hypothalamo-Hypophyseal System/metabolism , Sumatriptan/pharmacology , Sumatriptan/metabolism , Receptors, Glucocorticoid/metabolism , Serotonin/metabolism , Neuroinflammatory Diseases , Pituitary-Adrenal System/metabolism , Corticosterone , Stress, Psychological/metabolism , Social Isolation , FearABSTRACT
Scientific literature describes that sumatriptan is metabolized by oxidative deamination of its dimethylaminoethyl residue by monoamine oxidase A (MAO A) and not by cytochrome P450 (CYP)-mediated demethylation, as is usual for such structural elements. Using recombinant human enzymes and HPLC-MS analysis, we found that CYP enzymes may also be involved in the metabolism of sumatriptan. The CYP1A2, CYP2C19, and CYP2D6 isoforms converted this drug into N-desmethyl sumatriptan, which was further demethylated to N,N-didesmethyl sumatriptan by CYP1A2 and CYP2D6. Otherwise, sumatriptan and its two desmethyl metabolites were metabolized by recombinant MAO A but not by MAO B to the corresponding acetaldehyde, with sumatriptan being only a poor substrate for MAO A compared to the N-demethylated and the N,N-didemethylated derivatives.
Subject(s)
Cytochrome P-450 Enzyme System , Microsomes, Liver , Sumatriptan , Humans , Cytochrome P-450 CYP1A2/metabolism , Cytochrome P-450 CYP2D6/metabolism , Cytochrome P-450 Enzyme System/genetics , Cytochrome P-450 Enzyme System/metabolism , Microsomes, Liver/metabolism , Monoamine Oxidase/metabolism , Sumatriptan/metabolism , Sumatriptan/pharmacologyABSTRACT
BACKGROUND: In spite of the substantial therapeutic efficacy of triptans, their site of action is still debated. Subcutaneous sumatriptan is the most efficacious symptomatic treatment for cluster headache (CH) patients, showing therapeutic onset within a few minutes after injection even in migraine patients. However, whether subcutaneous sumatriptan is able to reach the CNS within this short time frame is currently unknown. METHODS: Here, by means of liquid chromatography/mass spectrometry, we investigated peripheral and brain distribution of subcutaneous sumatriptan soon after injection in rats at a dose equivalent to that used in patients. Tissue sumatriptan contents were compared to those of oxazepam, a prototypical lipophilic, neuroactive drug. RESULTS: We report that sumatriptan accumulated within brain regions of relevance to migraine and CH pathogenesis such as the hypothalamus and the brainstem as soon as 1 and 5 minutes after injection. Notably, sumatriptan brain distribution was faster than that of oxazepam, reaching concentrations exceeding its reported binding affinity for 5HT1B/D receptors, and in the range of those able to inhibit neurotransmitter release in vivo. CONCLUSION: Our findings indicate that sumatriptan distributes within the CNS soon after injection, and are in line with prompt pain relief by parenteral sumatriptan in CH patients.
Subject(s)
Brain/metabolism , Cluster Headache/metabolism , Serotonin 5-HT1 Receptor Agonists/metabolism , Sumatriptan/metabolism , Animals , Brain/drug effects , Chromatography, Liquid/methods , Cluster Headache/drug therapy , Injections, Subcutaneous , Male , Mass Spectrometry/methods , Rats , Rats, Wistar , Serotonin 5-HT1 Receptor Agonists/administration & dosage , Sumatriptan/administration & dosage , Time FactorsABSTRACT
This study focuses on the in vitro transdermal transport of sumatriptan succinate using combined iontophoresis and dissolving polymeric microneedle arrays. Permeation experiments were performed to evaluate the effects of formulation parameters on drug release from polyvinylpyrrolidone systems under mild electrical current (≤500 µA/cm2). The preparations consisted of hydrophilic, positively charged molecules encapsulated in a water-soluble and biocompatible polymeric material. Current densities of 100, 300, and 500 µA/cm2 were applied during a 6-h period using silver/silver chloride electrodes. The circular array consisted of 600 needles and occupied a 0.785 cm2 area. Tests, carried out with Franz diffusion cells and skin of Göttingen minipigs, showed that small decreases in the polymer concentration led to negligible lag times and marked increases in the cumulative amount of drug permeated in 6 h (Q6h) and in the flux (Jss). At 500 µA/cm2, Q6h and Jss nearly doubled for a microneedle loaded with 5% (w/w) sumatriptan and 20% (w/w) PVP (lag time = 0 min; Q6h = 2888 µg/cm2; Jss = 490 µg/cm2/h) relative to a system loaded with 5% (w/w) drug and 30% (w/w) PVP (lag time = 36 min; Q6h = 1437 µg/cm2; Jss = 266 µg/cm2/h).
Subject(s)
Skin/metabolism , Sumatriptan/administration & dosage , Sumatriptan/metabolism , Administration, Cutaneous , Animals , Drug Delivery Systems/methods , Drug Liberation/drug effects , Female , Iontophoresis/methods , Microinjections/methods , Needles , Povidone/chemistry , Skin Absorption/drug effects , Solubility/drug effects , Swine , Swine, MiniatureABSTRACT
In-vitro permeation studies were conducted to assess the feasibility of fabricating dissolving-microneedle-array systems to release sumatriptan succinate. The formulations consisted mainly of the encapsulated active ingredient and a water-soluble biologically compatible polymer, polyvinylpyrrolidone (PVP), approved by the U.S. Food and Drug Administration (FDA). Tests with Franz-type diffusion cells and Göttingen minipig skins showed an increase of the transdermal flux compared to passive diffusion. A preparation, containing 30% by mass of PVP and 8.7mg sumatriptan, produced a delivery rate of 395±31µg/cm2h over a 7-hour period after a negligible lag time of approximately 39min. Theoretically, a 10.7cm2 microneedle-array patch loaded with 118.8mg of the drug would provide the required plasma concentration, 72ng/mL, for nearly 7h.
Subject(s)
Drug Delivery Systems/methods , Microinjections/methods , Povidone/metabolism , Skin Absorption/physiology , Sumatriptan/metabolism , Animals , Female , Organ Culture Techniques , Pharmaceutic Aids/administration & dosage , Pharmaceutic Aids/metabolism , Povidone/administration & dosage , Skin Absorption/drug effects , Solubility , Sumatriptan/administration & dosage , Swine , Swine, Miniature , Vasoconstrictor Agents/administration & dosage , Vasoconstrictor Agents/metabolismABSTRACT
PURPOSE: Monoamine oxidases (MAOs) are non-CYP enzymes that contribute to systemic elimination of therapeutic agents, and localized on mitochondrial membranes. The aim of the present study was to validate quantitative estimation of metabolic clearance of MAO substrate drugs using human liver microsomes (HLMs). METHODS: Three MAO substrate drugs, sumatriptan, rizatriptan and phenylephrine, as well as four CYP substrates were selected, and their disappearance during incubation with HLMs or mitochondria (HLMt) was measured. Metabolic clearance (CL) was then calculated from the disappearance curve. RESULTS: CL obtained in HLMs for sumatriptan and a typical MAO substrate serotonin was correlated with that obtained in HLMt among ten human individual livers. Hepatic intrinsic clearance (CLint,vitro) estimated from CL in HLMs was 14-20 and 2-5 times lower than in vivo hepatic intrinsic clearance (CLint,vivo) obtained from literature for MAO and CYP substrates, respectively. Utilization of HLMs for quantitatively assessing metabolic clearance of MAO substrates was further validated by proteomics approach which has revealed that numerous proteins localized on inner and outer membranes of mitochondria were detected in both HLMs and HLMt. CONCLUSION: CLint,vitro values of MAO substrate drugs can be quantitatively estimated with HLMs and could be used for semi-quantitative prediction of CLint,vivo values.
Subject(s)
Microsomes, Liver/metabolism , Monoamine Oxidase/metabolism , Phenylephrine/metabolism , Sumatriptan/metabolism , Triazoles/metabolism , Tryptamines/metabolism , Humans , Kinetics , Metabolic Clearance Rate , Phenylephrine/pharmacology , Sumatriptan/pharmacology , Triazoles/pharmacology , Tryptamines/pharmacologyABSTRACT
The P-glycoprotein (Pgp) transporter reduces the penetration of a chemically diverse range of neurotherapeutics at the blood-brain barrier, but the molecular features of drugs and drug-Pgp interactions that drive transport remain to be clarified. In particular, the triptan neurotherapeutics, eletriptan (ETT) and sumatriptan (STT), were identified to have a >10-fold difference in transport rates despite being from the same drug class. Consistent with these transport differences, ETT activated Pgp-mediated ATP hydrolysis â¼2-fold, whereas STT slightly inhibited Pgp-mediated ATP hydrolysis by â¼10%. The interactions between them were also noncompetitive, suggesting that they occupy different binding sites on the transporter. Despite these differences, protein fluorescence spectroscopy revealed that the drugs have similar affinity to the transporter. NMR with Pgp and the drugs showed that they have distinct interactions with the transporter. Tertiary conformational changes probed by acrylamide quenching of Pgp tryptophan fluorescence with the drugs and a nonhydrolyzable ATP analog implied that the STT-bound Pgp must undergo larger conformational changes to hydrolyze ATP than ETT-bound Pgp. These results and previous transport studies were used to build a conformationally driven model for triptan transport with Pgp where STT presents a higher conformational barrier for ATP hydrolysis and transport than ETT.
Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Pyrrolidines/pharmacokinetics , Serotonin Receptor Agonists/pharmacokinetics , Sumatriptan/pharmacokinetics , Tryptamines/pharmacokinetics , ATP Binding Cassette Transporter, Subfamily B, Member 1/chemistry , Adenosine Triphosphate/metabolism , Animals , Blood-Brain Barrier/metabolism , Hydrolysis , Mice , Protein Conformation/drug effects , Pyrrolidines/metabolism , Serotonin Receptor Agonists/metabolism , Sumatriptan/metabolism , Tryptamines/metabolismABSTRACT
Sumatriptan succinate (SS) is a selective serotonin receptor agonist used for the treatment of migraine attacks, suffering from extensive first-pass metabolism and low oral bioavailability (â¼14%). The aim of this work is to compare the performance of different ready-made co-processed platforms (Pharmaburst®, Prosolv ODT®, Starlac®, Pearlitol Flash®, or Ludiflash®) in the formulation of SS sublingual orodispersible tablets (ODTs) using direct compression technique. The prepared SS ODT formulae were evaluated regarding hardness, friability, simulated wetting time, and in vitro disintegration and dissolution tests. Different mucoadhesive polymers-HPMC K4M, Carbopol®, chitosan, or Polyox®-were tested aiming to increase the residence time in the sublingual area. A pharmacokinetic study on healthy human volunteers was performed, using LC/MS/MS assay, to compare the optimum sublingual formula (Ph25/HPMC) with the conventional oral tablet Imitrex®. Results showed that tablets prepared using Pharmaburst® had significantly (p < 0.05) the lowest simulated wetting and in vitro disintegration times of 17.17 and 23.50 s, respectively, with Q 5 min of 83.62%. HPMC showed a significant (p < 0.05) increase in the residence time from 48.44 to 183.76 s. The relative bioavailability was found to be equal to 132.34% relative to the oral tablet Imitrex®. In conclusion, Pharmaburst® was chosen as the optimum ready-made co-processed platform that can be successfully used in the preparation of SS sublingual tablets for the rapid relief of migraine attacks.
Subject(s)
Sumatriptan/administration & dosage , Sumatriptan/chemistry , Tablets/administration & dosage , Tablets/chemistry , Administration, Oral , Administration, Sublingual , Biological Availability , Chemistry, Pharmaceutical/methods , Excipients/chemistry , Hardness , Humans , Male , Solubility , Sumatriptan/metabolism , WettabilityABSTRACT
The advances in laser technology have led to its rapidly expanding applications in dermatology. This study aims at the novel use of a non-ablative fractional laser to enhance transdermal permeation of diclofenac sodium and sumatriptan succinate. The effects of the laser on skin were characterized visually with dye binding, scanning electron microscopy, pore permeability index, and histology. In vitro transdermal permeation of drugs through laser treated and untreated human dermatomed skin was analyzed over 24 h and quantified by HPLC. Drug transport through untreated skin resulted in transdermal delivery of 72.61 µg/cm2 ± 50.35 and 22.80 ± 0.64 µg/cm2 of diclofenac sodium and sumatriptan succinate, respectively. Laser treatment of skin significantly increased (p < 0.005) delivery of diclofenac sodium to 575.66 ± 207.18 µg/cm2 and sumatriptan succinate to 498.32 ± 97.54 µg/cm2. This is a first of its kind study that demonstrates the use of 1410 nm non-ablative fractional laser to enhance transdermal permeation of 2 small molecular weight drugs.
Subject(s)
Diclofenac/metabolism , Drug Delivery Systems/methods , Laser Therapy/methods , Skin Absorption/physiology , Sumatriptan/metabolism , Administration, Cutaneous , Diclofenac/administration & dosage , Electric Impedance , Humans , Organ Culture Techniques , Skin Absorption/drug effects , Sumatriptan/administration & dosageABSTRACT
OBJECTIVE: To explore the potential of non-ionic surfactants as novel intranasal absorption enhancers. METHODS: Taking sumatriptan succinate (SMS) as a model drug, influence of different non-ionic surfactants, including laurate sucrose ester (SE), cremophor EL and poloxamer 188, on the intranasal absorption of SMS was investigated using an in situ nasal perfusion technique in rats. Ciliotoxicity of the non-ionic surfactants was evaluated using an in situ toad palate model. In vivo behavior of the selected formulations was studied in rats. RESULTS: All the non-ionic surfactants investigated increased the intranasal absorption of SMS remarkably but with varied extent and trend. Moreover, it was revealed that at the same concentration, laurate SE had better permeation-enhancing effect than that of cremophor EL and poloxamer 188. The ciliotoxicity results showed that all the non-ionic surfactants were regarded as safe at selected concentrations. Based on the in situ absorption data and ciliotoxicity results, the following three samples, 0.5% laurate SE, 0.1% cremophor EL and 0.5% poloxamer 188 were selected for in vivo absorption studies in rats. Among them, 0.5% laurate SE group presented the highest enhancing effect, followed by 0.1% cremophor EL and 0.5% poloxamer 188 group, with absolute bioavailability 29.99%, 22.64% and 20.90%, respectively. CONCLUSIONS: Laurate SE is a promising intranasal absorption enhancer.
Subject(s)
Nasal Absorption/drug effects , Sumatriptan/chemistry , Surface-Active Agents/chemistry , Administration, Intranasal/methods , Animals , Biological Availability , Chemistry, Pharmaceutical/methods , Glycerol/analogs & derivatives , Glycerol/chemistry , Laurates/chemistry , Male , Nasal Mucosa/metabolism , Poloxamer/chemistry , Rats , Rats, Sprague-Dawley , Sumatriptan/metabolismABSTRACT
The present investigation is aimed at development and characterization of sumatriptan succinate orodispersible tablets (ODTs) prepared by freeze drying technology. The tablet excipients were screened and the composition was optimized based on parameters which involved general appearance, tablet size and shape, uniformity of weight, mechanical properties, surface pH, moisture analysis, drug content, wetting time, in vitro and in vivo disintegration time. Furthermore, fourier transform infrared spectroscopy, differential scanning calorimetry, scanning electron micrograph of cross-section of the tablet and in vitro dissolution studies were performed. Studies revealed that formulation containing gelatin-mannitol (3.75% w/v and 3.5% w/v, respectively) with camphor as a volatile pore forming agent exhibited superior properties with disintegration time of less than 10 s. Furthermore, in vitro release studies revealed 90% release of drug from developed dosage form within 10 min, thus suggesting rapid drug dissolution followed by faster onset of action, which forms a strong rationale for development of ODTs of sumatriptan succinate. The developed technology is simple, which involves few steps and can be easily scaled up. Thus, it holds enormous potential for commercial exploitation.
Subject(s)
Chemistry, Pharmaceutical/methods , Sumatriptan/chemical synthesis , Sumatriptan/metabolism , Administration, Oral , Freeze Drying/methods , Humans , Mouth Mucosa/drug effects , Mouth Mucosa/metabolism , Sumatriptan/administration & dosage , TabletsABSTRACT
In this paper, two techniques, differential scanning calorimetry (DSC) and phosphorus nuclear magnetic resonance ((31)P-NMR), have been used to characterize sumatriptan succinate-loaded charged liposomes. To complete the results obtained by DSC a hot stage microscopy (HSM) technique was used. Data concerning the drug entrapment efficiency were published in a previous paper. The differences in data concerning encapsulation into negatively and positively-charged vesicles, indicated an influence of drug in the structural conformation of lipids in the bilayer. Moreover, the inability to formulate chargeless vesicles contributed to the opinion that a physical formulation study might be relevant. Phosphatidylcholine and cholesterol were used as lipid film forming agents, whereas stearylamine (positive) and dicetylphosphate (negative) were added as charge-inducing agents. DSC studies demonstrated that phosphatidylcholine caused the disappearance of the melting peak (Tm) of sumatriptan succinate because a drug dissolution process occurs. In addition, thermograms showed interesting interactions between stearylamine and dicetylphosphate with sumatriptan succinate favoring drug entrapment into the liposomes. In the present work, (31)P-NMR technique demonstrated that the structural conformation of lipids in the membrane affected drug encapsulation into multilamellar (MLVs) and unilamellar (LUVs) vesicles. Bilayer structure in a liquid crystalline phase of the positively-charged REV liposomes membrane has demonstrated a high structural stability and a better encapsulation efficacy for sumatriptan succinate than negatively-charged TLE and REV liposomes. Therefore, phosphatidylcholine interaction with sumatriptan succinate appears to be the cause of the inability to obtain neutral sumatriptan succinate liposomes.
Subject(s)
Calorimetry, Differential Scanning , Cholesterol/chemistry , Lipid Bilayers/metabolism , Liposomes/chemistry , Magnetic Resonance Spectroscopy , Phosphatidylcholines/chemistry , Sumatriptan/chemistry , Amines/pharmacology , Cholesterol/metabolism , Organophosphates/pharmacology , Phosphatidylcholines/metabolism , Sumatriptan/metabolismABSTRACT
Triptans and analgetic nonsteroidal inflammatory drugs reduce acute pain syndromes in migraine. A further treatment option for an acute headache attack in patients with migraine may be the application of cyclooxygenase-2-specific inhibitors, as they have anti-inflammatory and analgesic properties. The objective of this pilot study was to investigate the effects of an oral fast-dissolving tablet of 10 mg of rizatriptan, an intravenous infusion of 40 mg of parecoxib, and a subcutaneous pen injection of sumatriptan (6 mg/0.5 mL) on pain relief in 3 cohorts of patients with episodic migraine. They were treated owing to the acute onset of a pain attack as a case of emergency. They were randomized to treatment with sumatriptan, rizatriptan, or parecoxib. The participants completed a visual analog scale for pain intensity at baseline before the drug administration and then after intervals of 20, 30, 60, and 120 minutes. Rizatriptan, parecoxib, and sumatriptan reduced pain symptoms. Twenty and 30 minutes after drug intake, rizatriptan was more efficacious than parecoxib and sumatriptan, and parecoxib was more effective than sumatriptan. Only a significant difference between rizatriptan and sumatriptan was found after 60 and 120 minutes. This trial demonstrates the effectiveness of a parecoxib infusion in the treatment of acute migraine and that the circumvention of the first pass effect of the liver by rizatriptan may be beneficial for fast pain relief.
Subject(s)
Isoxazoles/administration & dosage , Migraine Disorders/drug therapy , Sumatriptan/administration & dosage , Triazoles/administration & dosage , Tryptamines/administration & dosage , Acute Disease , Administration, Oral , Adult , Cohort Studies , Female , Humans , Infusions, Intravenous , Injections, Subcutaneous , Isoxazoles/metabolism , Male , Middle Aged , Migraine Disorders/metabolism , Migraine Disorders/pathology , Pain Measurement/drug effects , Pain Measurement/methods , Pilot Projects , Sumatriptan/metabolism , Treatment Outcome , Triazoles/metabolism , Tryptamines/metabolismABSTRACT
Sumatriptan, a relatively hydrophilic triptan, based on several animal studies has been regarded to be unable to cross the blood-brain barrier (BBB). In more recent animal studies there are strong indications that sumatriptan to some extent can cross the BBB. The CNS adverse events of sumatriptan in migraine patients and normal volunteers also indicate a more general effect of sumatriptan on CNS indicating that the drug can cross the BBB in man. It has been discussed whether a defect in the BBB during migraine attacks could be responsible for a possible central effect of sumatriptan in migraine. This review suggests that there is no need for a breakdown in the BBB to occur in order to explain a possible central CNS effect of sumatriptan.
Subject(s)
Blood-Brain Barrier/physiology , Serotonin Receptor Agonists/metabolism , Sumatriptan/metabolism , Animals , Central Nervous System/drug effects , Dose-Response Relationship, Drug , Humans , Migraine Disorders/drug therapy , Migraine Disorders/pathology , Serotonin Receptor Agonists/therapeutic use , Sumatriptan/therapeutic useABSTRACT
BACKGROUND: The absolute bioavailability of subcutaneous (s.c.) sumatriptan is 96-100%. The decay curve for plasma concentration after 6 mg s.c. sumatriptan (ie, after T(max) = about 0.2 hours) includes a large distribution component. Metabolism by monoamine oxidase-A (MAO-A) leads to about 40% of the s.c. dose appearing in the urine as the inactive indole acetic acid. Product labeling states that co-administration of an inhibitor of MAO-A (a MAOI-A) causes a 2-fold increase in sumatriptan plasma concentrations, and a 40% increase in elimination half-life. OBJECTIVE: The objective of this study is to determine whether MAOI-A therapy should deter the use of 6 mg s.c. sumatriptan on pharmacokinetic grounds. METHODS: Summary pharmacokinetic data were taken from the literature and from GlaxoSmithKline (GSK) study C92-050. Half-times were converted into rate constants, which were then used in a parsimonious compartmental model (needing only 3 simultaneous differential equations). Acceptance criteria for the model included observed plasma sumatriptan concentrations at T(max), 1, 2, and 10 hours post-dose. A set of 1000 concentration measurements at a resolution of 36 seconds was generated. The model was then perturbed with elimination constants observed during concomitant moclobemide administration, creating a second set of concentration measurements. The 2 sets were then plotted, examined for their differences, and integrated for a second time to obtain and compare areas under the curve (AUCs). RESULTS: The greatest absolute difference between the 2 sets of measurements was 2.85 ng/mL at t = 2.95 hours. A 2-fold difference between the 2 sets occurred only after t = 5.96 hours, when the concentration in the presence of the MAOI-A was 3.72 ng/mL (or <4% of C(max)). At t = 10 hours, the concentrations in both sets were <1 ng/mL (ie, below the lower limit of assay quantitation), and AUC(0-10h) was 97.4 and 117 ng.hour/mL in the absence and presence of the MAOI-A. CONCLUSIONS: There are no pharmacokinetic grounds to deter co-administration of an MAOI-A and subcutaneous sumatriptan. The dominance of the distribution phase and completeness of absorption of a 6 mg dose of s.c. sumatriptan explains the trivial effect size of the MAOI-A on plasma sumatriptan concentrations. Importantly, these findings should not be extrapolated to other routes of administration for sumatriptan.
Subject(s)
Drug Interactions/physiology , Monoamine Oxidase Inhibitors/adverse effects , Monoamine Oxidase/metabolism , Serotonin Receptor Agonists/pharmacokinetics , Sumatriptan/pharmacokinetics , Brain/drug effects , Brain/metabolism , Brain/physiopathology , Computer Simulation , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Indoleacetic Acids/metabolism , Migraine Disorders/drug therapy , Migraine Disorders/metabolism , Migraine Disorders/physiopathology , Pharmacokinetics , Serotonin/metabolism , Serotonin Receptor Agonists/blood , Serotonin Receptor Agonists/metabolism , Sumatriptan/blood , Sumatriptan/metabolismABSTRACT
We have successfully obtained sumatriptan transdermal systems with different polymer compositions: methyl cellulose (MC), polyvinyl pyrrolidone (PVP) and a polyvinyl pyrrolidone (PVP)-polyvinyl alcohol (PVA) mixture. The systems contained 1,2-propylenglycol (MC) or sorbitol as a plasticizer (PVP and PVP-PVA), methacrylate copolymer as an adhesive agent, and an occlusive liner. Azone (5%, w/w) was incorporated into all the systems as a percutaneous enhancer. Transdermal systems are thin, transparent and non-adhesive when in a dry state. The permeation of sumatriptan succinate across pig ear skin was studied using the systems prepared. The formulation with MC polymer produced a statistically significant increment with respect to the PVP and PVP-PVA formulations (p < 0.05). Azone incorporation into the systems produced an increment in the sumatriptan flux values of all three transdermal systems with respect to those of the controls (p < 0.05). In addition, the application of iontophoresis to the wet methyl cellulose-Azone formulation produced a much higher increase of sumatriptan transdermal flux.
Subject(s)
Drug Carriers , Migraine Disorders/drug therapy , Polymers/chemistry , Serotonin Receptor Agonists/administration & dosage , Sumatriptan/administration & dosage , Vasoconstrictor Agents/administration & dosage , Administration, Cutaneous , Animals , Azepines/chemistry , Chemistry, Pharmaceutical , Diffusion Chambers, Culture , Drug Compounding , Iontophoresis , Kinetics , Methylcellulose/chemistry , Permeability , Plasticizers/chemistry , Polymethacrylic Acids/chemistry , Polyvinyl Alcohol/chemistry , Povidone/chemistry , Propylene Glycol/chemistry , Serotonin Receptor Agonists/chemistry , Serotonin Receptor Agonists/metabolism , Skin/metabolism , Skin Absorption , Sorbitol/chemistry , Sumatriptan/chemistry , Sumatriptan/metabolism , Swine , Technology, Pharmaceutical/methods , Tissue Adhesives/chemistry , Vasoconstrictor Agents/chemistry , Vasoconstrictor Agents/metabolismABSTRACT
Abnormalities in serotonergic function are thought to be important in the pathology of schizophrenia. Postmortem CNS studies suggest that levels of serotonin receptors may be altered in the cortex of subjects with schizophrenia. Seeking to expand this hypothesis we have examined the effect of schizophrenia and antipsychotic drug treatments on the levels of cortical serotonin7, 1D and 1F receptors. There was a significant decrease in the binding of [3H]SB 269970 to the serotonin7 receptor in Brodmann's area 9 from subjects with schizophrenia compared to controls (Mean+/-S.E.M.: 8.3+/-0.76 vs. 11.0+/-0.64 fmol/mg ETE; p<0.05) and an increase in the binding of that radioligand in the cortex of rats treated with haloperidol (p=0.03). There were no significant differences in [3H]sumatriptan binding to the serotonin1D or serotonin1F receptor in Brodmann's area 9 from subjects with schizophrenia. There was a significant increase in [3H]sumatriptan binding to the serotonin1D in binding Layer 2 from subjects who had potentially died by suicide that was not present in other binding layers or for the serotonin1F or serotonin7 receptors. There was decrease in [3H]sumatriptan binding to the serotonin1D, but not serotonin1F, receptors across all cortical binding layers in rats treated with haloperidol. These data would be consistent with the hypothesis that decreased levels of serotonin7 receptors in Brodmann's area 9 may be involved in the pathological processes of schizophrenia and that levels of cortical serotonin7 and 1D receptors can be affected by antipsychotic drug treatment.
Subject(s)
Antipsychotic Agents/therapeutic use , Chlorpromazine/therapeutic use , Prefrontal Cortex/metabolism , Receptor, Serotonin, 5-HT1D/genetics , Receptor, Serotonin, 5-HT1D/metabolism , Receptors, Serotonin/genetics , Receptors, Serotonin/metabolism , Schizophrenia , Suicide/statistics & numerical data , Adult , Aged , Binding Sites , Case-Control Studies , Female , Humans , Male , Middle Aged , Schizophrenia/drug therapy , Schizophrenia/genetics , Schizophrenia/metabolism , Sumatriptan/metabolism , Receptor, Serotonin, 5-HT1FABSTRACT
Sumatriptan is the first of a novel class of medications referred to as triptans. Since its approval for migraine in the 1990s, six other triptan products have received FDA approval. Despite the proliferation of triptans, sumatriptan remains the most frequently prescribed product in this therapeutic class. Sumatriptan has been instrumental in defining a biological basis for migraine. It is effective in treating migraine with or without aura, well tolerated and, when properly prescribed, safe. Sumatriptan injection is the only member of the triptan class approved for treatment of cluster headache. Studies with sumatriptan have also advanced the therapeutic intervention paradigm that permits patients to treat earlier and avoid substantial disability. Numerous pharmacoeconomic studies have demonstrated that sumatriptan decreases work loss productivity and improves quality of life.
Subject(s)
Sumatriptan/pharmacology , Animals , Cardiovascular Diseases/chemically induced , Drug Interactions , Drug Tolerance , Humans , Naproxen/pharmacology , Sumatriptan/administration & dosage , Sumatriptan/adverse effects , Sumatriptan/metabolism , Treatment OutcomeABSTRACT
Iontophoretic transdermal delivery of sumatriptan was investigated in vitro. Among the conditions tested, 0.25 mA/cm2 and low ionic strength (NaCl 25 mM) was the best experimental condition to increase its transport across the skin. The flux increased 385-fold respective to passive diffusion, thus resulting in a transdermal flux of sumatriptan of 1273+/-83 nmol/cm2 h.
Subject(s)
Iontophoresis , Serotonin Receptor Agonists/metabolism , Skin Absorption , Skin/metabolism , Sumatriptan/metabolism , Administration, Cutaneous , Animals , Buffers , Ear , Osmolar Concentration , Osmosis , Skin/chemistry , Sodium Chloride/chemistry , Sumatriptan/chemistry , Swine , Time FactorsABSTRACT
The goal of this exploratory pilot study was to use gamma scintigraphy to evaluate, under physiological conditions, disintegration profiles of encapsulated and nonencapsulated formulations of 100 mg sumatriptan. Using a crossover design, healthy volunteers (n = 10) ingested 100-mg doses of sumatriptan tablets radiolabeled with 111Indium, as well as encapsulated sumatriptan tablets that were prepared similarly, then placed within a gelatin capsule and backfilled with an excipient blend radiolabeled with 99mTechnetium. A gamma camera recorded scintigraphic images until 5 hours postdose. Initial disintegration of the gelatin capsule was observed at a mean (range) of 5 minutes (1-11 minutes); disintegration was complete within 14 minutes (5-24 minutes). For nonencapsulated versus encapsulated tablets, the mean (+/- standard deviation) time to initial disintegration (6 +/- 5 minutes vs 8 +/- 5 minutes) and time to complete disintegration (18 +/- 14 minutes vs 16 +/- 7 minutes) were comparable. Results of this study demonstrate that encapsulated and nonencapsulated sumatriptan have equivalent in vivo dissolution rates.